DDInter336 DDInter1143
Celecoxib, a selective cyclooxygenase-2 (COX-2) inhibitor, is a nonsteroidal anti-inflammatory drug (NSAID) which is known for its decreased risk of causing gastrointestinal bleeding compared to other NSAIDS. It is used to manage symptoms of various types of arthritis pain and in familial adenomatous polyposis (FAP) to reduce precancerous polyps in the colon. It is marketed by Pfizer under the brand name Celebrex, and was initially granted FDA approval in 1998. Interestingly, selective COX-2 inhibitors (especially celecoxib), have been evaluated as potential cancer chemopreventive and therapeutic drugs in clinical trials for a variety of malignancies.
Meloxicam is a nonsteroidal anti-inflammatory drug (NSAID) used to relieve various types of pain, including pain caused by musculoskeletal conditions, osteoarthritis, and rheumatoid arthritis. With a longer half-life than most other NSAIDS, it is a favorable option for those who require once-daily dosing. Meloxicam is available in oral, transdermal, and intravenous formulations. It is a preferential COX-2 inhibitor, purportedly reducing the risk of adverse gastrointestinal tract effects, however, this is a topic of controversy.[A190198,A190201]
Celecoxib {u} (Compound) binds {v} (Gene) CYP2C9
CYP2C9 {u} (Gene) is bound by {v} (Compound) Meloxicam
Celecoxib {u} (Compound) palliates {v} (Disease) systemic lupus erythematosus
systemic lupus erythematosus {u} (Disease) is palliated by {v} (Compound) Meloxicam
Celecoxib {u} (Compound) is included by {v} (Pharmacologic Class) Nonsteroidal Anti-inflammatory Compounds
Nonsteroidal Anti-inflammatory Compounds {u} (Pharmacologic Class) includes {v} (Compound) Meloxicam
Celecoxib {u} (Compound) causes {v} (Side Effect) Stevens-Johnson syndrome
Stevens-Johnson syndrome {u} (Side Effect) is caused by {v} (Compound) Meloxicam
Celecoxib {u} (Compound) binds {v} (Gene) CYP2C9
CYP2C9 {u} (Gene) is bound by {v} (Compound) Piroxicam
Piroxicam {u} (Compound) resembles {v} (Compound) Meloxicam
Celecoxib {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Repaglinide
Repaglinide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Meloxicam
Celecoxib {u} (Compound) binds {v} (Gene) ABCC4
ABCC4 {u} (Gene) is bound by {v} (Compound) Flurbiprofen
Flurbiprofen {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Meloxicam
Celecoxib {u} (Compound) palliates {v} (Disease) systemic lupus erythematosus
systemic lupus erythematosus {u} (Disease) is associated with {v} (Gene) PTGS2
PTGS2 {u} (Gene) is bound by {v} (Compound) Meloxicam
Celecoxib {u} (Compound) palliates {v} (Disease) systemic scleroderma
systemic scleroderma {u} (Disease) resembles {v} (Disease) systemic lupus erythematosus
systemic lupus erythematosus {u} (Disease) is palliated by {v} (Compound) Meloxicam
Celecoxib {u} (Compound) palliates {v} (Disease) ankylosing spondylitis
ankylosing spondylitis {u} (Disease) is palliated by {v} (Compound) Piroxicam
Piroxicam {u} (Compound) resembles {v} (Compound) Meloxicam
Celecoxib (Compound) binds CYP2C9 (Gene) and CYP2C9 (Gene) is bound by Meloxicam (Compound)
Celecoxib (Compound) palliates systemic lupus erythematosus (Disease) and systemic lupus erythematosus (Disease) is palliated by Meloxicam (Compound)
Celecoxib (Compound) is included by Nonsteroidal Anti-inflammatory Compounds (Pharmacologic Class) and Nonsteroidal Anti-inflammatory Compounds (Pharmacologic Class) includes Meloxicam (Compound)
Celecoxib (Compound) causes Stevens-Johnson syndrome (Side Effect) and Stevens-Johnson syndrome (Side Effect) is caused by Meloxicam (Compound)
Celecoxib (Compound) binds CYP2C9 (Gene) and CYP2C9 (Gene) is bound by Piroxicam (Compound) and Piroxicam (Compound) resembles Meloxicam (Compound)
Celecoxib (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Repaglinide (Compound) and Repaglinide may cause a moderate interaction that could exacerbate diseases when taken with Meloxicam
Celecoxib (Compound) binds ABCC4 (Gene) and ABCC4 (Gene) is bound by Flurbiprofen (Compound) and Flurbiprofen may cause a moderate interaction that could exacerbate diseases when taken with Meloxicam
Celecoxib (Compound) palliates systemic lupus erythematosus (Disease) and systemic lupus erythematosus (Disease) is associated with PTGS2 (Gene) and PTGS2 (Gene) is bound by Meloxicam (Compound)
Celecoxib (Compound) palliates systemic scleroderma (Disease) and systemic scleroderma (Disease) resembles systemic lupus erythematosus (Disease) and systemic lupus erythematosus (Disease) is palliated by Meloxicam (Compound)
Celecoxib (Compound) palliates ankylosing spondylitis (Disease) and ankylosing spondylitis (Disease) is palliated by Piroxicam (Compound) and Piroxicam (Compound) resembles Meloxicam (Compound)